We have located links that may give you full text access.
Early and long-term outcomes following redo mitral valve surgery in patients with prior minimally invasive mitral valve surgery.
Interdiscip Cardiovasc Thorac Surg 2024 March 19
OBJECTIVES: The frequency of minimally invasive mitral valve surgery has steadily increased over the last decades and therefore surgeons are now encountering an increasing number of patients requiring mitral valve reoperations post-minimally invasive mitral valve surgery. The aim of this study was to analyze the early postoperative outcomes and the long-term survival in patients who undergo reoperative mitral valve surgery following previous minimally invasive surgery.
METHODS: Patients who underwent redo mitral valve surgery following prior minimally invasive mitral valve surgery between January 2002 and December 2021 were included in our analysis. Study data were prospectively collected and retrospectively analyzed. The primary outcomes were 30-day mortality and long-term survival.
RESULTS: Among the 187 included patients, 34 (18.2%) underwent repeat mitral valve repair and 153 (81.8%) mitral valve replacement. Median age was 66 years (Interquartile range 56-74) and 80 (42.8%) patients were female. Redo mitral valve surgery was performed through median sternotomy in 169 patients (90.4%). A total of 77 (41.2%) patients had additional concomitant procedures. Median ICU stay was 1 day (1-5). The 30-day mortality was 6.4% (12/187). Estimated survival at 5 and 12 years was 61.8% and 38.3%, respectively. Preoperative stroke (HR 3.28, 95% CI 1.37-7.85, p = 0.007) as well as infective endocarditis (HR 1.85; 95% CI 1.09-3.11, p = 0.021) were independent predictors of long-term mortality.
CONCLUSIONS: Redo mitral valve surgery following prior minimally invasive mitral valve surgery can be performed safely with low early perioperative mortality and acceptable long-term survival. Preoperative stroke, infective endocarditis and concomitant tricuspid valve surgery are independent predictors of long-term mortality.
METHODS: Patients who underwent redo mitral valve surgery following prior minimally invasive mitral valve surgery between January 2002 and December 2021 were included in our analysis. Study data were prospectively collected and retrospectively analyzed. The primary outcomes were 30-day mortality and long-term survival.
RESULTS: Among the 187 included patients, 34 (18.2%) underwent repeat mitral valve repair and 153 (81.8%) mitral valve replacement. Median age was 66 years (Interquartile range 56-74) and 80 (42.8%) patients were female. Redo mitral valve surgery was performed through median sternotomy in 169 patients (90.4%). A total of 77 (41.2%) patients had additional concomitant procedures. Median ICU stay was 1 day (1-5). The 30-day mortality was 6.4% (12/187). Estimated survival at 5 and 12 years was 61.8% and 38.3%, respectively. Preoperative stroke (HR 3.28, 95% CI 1.37-7.85, p = 0.007) as well as infective endocarditis (HR 1.85; 95% CI 1.09-3.11, p = 0.021) were independent predictors of long-term mortality.
CONCLUSIONS: Redo mitral valve surgery following prior minimally invasive mitral valve surgery can be performed safely with low early perioperative mortality and acceptable long-term survival. Preoperative stroke, infective endocarditis and concomitant tricuspid valve surgery are independent predictors of long-term mortality.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app